Riemser Pharma acquires French drugmaker Keocyt

12 May 2014

German specialty pharmaceutical company Riemser Pharma (formerly Riemser Arzneimittel) said today that it has acquired privately-held French specialty pharmaceutical company Keocyt. Financial terms of the deal were not disclosed.

With this acquisition, Riemser says it has reached another important milestone of its international growth strategy and significantly strengthens its position on the French and neighboring Southern European markets.

Keocyt brings to market pharmaceutical products that are applied in the treatment of rare diseases, especially in cancer therapy and neurology. The Paris based company was founded in 2007 by two former employees of Pfizer and markets the drugs Zanosar (streptozocin), Estracyt (estramustine), Prodilantin and Dilantin (fosphenytopne) used for the treatment of certain pancreatic endocrine tumors, prostate cancer and status epilepticus, respectively.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK